ClinicalTrials.gg
CompletedNCT01012323Updated Mar 16, 2017Results posted

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

A Phase 3 interventional study of NewGam in Primary Immunodeficiency Diseases, sponsored by Octapharma. Completed at 7 sites in United States. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-16.

Sponsored by Octapharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
2 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
6th of 26
51 · median 45
Started
2010
the only one that year
Phase 3
18 of 27
2 open now
Registered
8th of 27
by date
Lead sponsor
3 of 27
Octapharma

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 6th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2010, is one of 18 in phase 3, and was the 8th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of this study was to determine the efficacy of NewGam in preventing serious bacterial infections and to determine the pharmacokinetic profile of NewGam. The safety of NewGam and its effect on quality of life were also evaluated.

Read the detailed description

NewGam is a new 10% human normal immunoglobulin (IVIG) solution developed by Octapharma for intravenous administration. It is supplied as a liquid formulation ready to use. The primary therapeutic use of immunoglobulins is to provide antibodies to prevent viral and bacterial diseases (replacement therapy). IVIG has proved to be useful in a variety of clinical conditions other than for replacement of immunoglobulins; IVIG exhibits an immunomodulatory effect. Children and adults with a Primary Immunodeficiency Disease (PID) have an increased risk of recurrent bacterial and viral infections that typically attack the respiratory tract (sinusitis, bronchitis, pneumonia) but can also affect the gastrointestinal tract (gastroenteritis). Theses diseases can be severe and can lead to substantial morbidity. Responses to antibacterial therapy are often poor. At present, most primary immune deficiencies are not curable, but IVIGs have been shown to decrease the total number of severe infections and the duration of hospitalization.

03

Conditions studied

  • Primary Immunodeficiency Diseases

Keywords

  • PID
04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of ≥ 2 years and ≤ 75 years.
  • Confirmed diagnosis of common variable immunodeficiency (CVID) or X-linked agammaglobulinemia (XLA).
  • Previously treated with a commercial immune globulin intravenous (human) every 21-28 days for at least 6 infusion intervals at a constant dose between 200 and 800 mg/kg body weight.

Exclusion criteria

Exclusion Criteria:

  • Acute infection requiring intravenous antibiotic treatment within 2 weeks prior to and during the screening period.
  • Exposure to blood or any blood product or derivative, other than commercially available intravenous immunoglobulin (IVIG), within the past 3 months prior to enrollment.
  • Ongoing history of or persistent reactions to blood or plasma derived products, or any component of the product.
  • Requirement of any routine pre-medication for IVIG infusion.
  • Severe liver function impairment ( [ALAT] 3x > ).
  • Presence of renal function impairment (creatinine > 120 μmol/L), or predisposition for acute renal failure (eg, any degree of pre-existing renal insufficiency or routine treatment with known nephritic drugs).
  • History of hemolytic anemia.
  • History of diabetes mellitus.
  • Congestive heart failure (NYHA) class III or IV.
  • Non-controlled arterial hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 90 mmHg).
  • History of deep vein thrombosis or thrombotic complications of IVIG therapy.
  • A positive result at screening on any of the following viral markers: (HIV), virus (HCV), virus (HBV).
  • Treatment with (oral or parenteral, long-term, ie, 30 days or more, not intermittent or burst, daily, ≥ 0.15 mg of prednisone or equivalent/kg/day), or immunomodulatory drugs.
  • Planned vaccination during the study period.
  • Treatment with any investigational agent within 3 months prior to enrollment.
  • Known or suspected to abuse alcohol, drugs, psychotropic agents or other chemicals within the past 12 months prior to enrollment.
  • Pregnant or nursing women.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    NewGam

    Participants received NewGam 200-800 mg/kg intravenously every 3 weeks (17 infusions) or 4 weeks (13 infusions) for 1 year.

    Biological: NewGam

Interventions

  • BiologicalNewGam

    The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.

    Also known as: Human normal immunoglobulin

06

What researchers measure

Primary outcomes

  1. Number of Serious Bacterial Infections Per Person-year of Treatment

    The number of serious bacterial infections per person-year of treatment was calculated by the following formula: Total number of serious bacterial infections / patient-years on NewGam treatment. Serious bacterial infections were defined as bacteraemia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess.

    Time frame: Baseline to end of the study (up to 12 months)

Secondary outcomes

  1. IgG Trough Level Concentration

    Total IgG trough concentrations were measured in serum samples taken before each infusion.

    Time frame: Baseline to end of the study (up to 12 months)

  2. Trough Level Concentration of Antibodies Against Haemophilus Influenzae

    Trough level concentrations of antibodies against Haemophilus influenzae were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

    Time frame: Baseline to end of the study (up to 12 months)

  3. Trough Level Concentration of Antibodies Against Measles

    Trough level concentrations of antibodies against measles were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

    Time frame: Baseline to end of the study (up to 12 months)

  4. Trough Level Concentration of Antibodies Against Streptococcus Pneumoniae

    Trough level concentrations of antibodies against Streptococcus pneumoniae (serotypes types 6B, 14, 9V, 18C, 19F, 4, and 23F) were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

    Time frame: Baseline to end of the study (up to 12 months)

  5. Trough Level Concentration of Antibodies Against Cytomegalovirus

    Trough level concentrations of antibodies against cytomegalovirus were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

    Time frame: Baseline to end of the study (up to 12 months)

  6. Trough Level Concentration of Antibodies Against Tetanus

    Trough level concentrations of antibodies against tetanus were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

    Time frame: Baseline to end of the study (up to 12 months)

  7. Trough Level Concentration of Antibodies Against Varicella-zoster Virus

    Trough level concentrations of antibodies against varicella-zoster virus were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

    Time frame: Baseline to end of the study (up to 12 months)

  8. Total Number of Infections

    The number of infections included serious bacterial infections (bacterial pneumonia, bacteraemia/sepsis, osteomyelitis/septic arthritis, visceral abscess, bacterial meningitis) and other infections. For other infections, the Medical Dictionary for Regulatory Activities (MedDRA) preferred term was used to determine the type of infection. They were grouped into the following categories as determined by a medical expert: Ear infections, eye infections, infections of the gastrointestinal tract, infections of the genitourinary tract, upper respiratory tract infections, lower respiratory tract infections, infections of the skin, and infections not elsewhere classified.

    Time frame: Baseline to end of the study (up to 12 months)

  9. Number of Non-serious Infections

    The MedDRA preferred term was used to determine the type of non-serious infection. They were grouped into the following categories as determined by a medical expert: Ear infections, eye infections, infections of the gastrointestinal tract, infections of the genitourinary tract, upper respiratory tract infections, lower respiratory tract infections, infections of the skin, and infections not elsewhere classified. The total number of infections and the number in each category are reported.

    Time frame: Baseline to end of the study (up to 12 months)

  10. Time to Resolution of Serious and Other Infections

    Since infections were reported as adverse events, the time to resolution of an infection was the time from the start date of the infection adverse event to the end date of the infection adverse event.

    Time frame: Baseline to end of the study (up to 12 months)

  11. Percentage of Participants Treated With Antibiotics

    The total percentage of participants treated with antibiotics, as well as, the percentage of participants treated with antibiotics therapeutically and prophylactically are reported.

    Time frame: Baseline to end of the study (up to 12 months)

  12. Number of Antibiotic Treatment Episodes Per Person-year of Treatment

    The number of antibiotic treatment episodes per person-year of treatment was calculated by the following formula: Total number of antibiotic treatment episodes / patient-years of NewGam treatment.

    Time frame: Baseline to end of the study (up to 12 months)

  13. Number of Antibiotic Treatment Days Per Person-year of Treatment

    The number of antibiotic treatment days per person-year of treatment was calculated by the following formula: Total number of antibiotic treatment days / patient-years of NewGam treatment.

    Time frame: Baseline to end of the study (up to 12 months)

  14. Number of Participants Hospitalized Due to an Infection

    Time frame: Baseline to end of the study (up to 12 months)

  15. Percentage of Participants With at Least 1 Episode of Fever

    Time frame: Baseline to end of the study (up to 12 months)

  16. Percentage of Participants That Missed School or Work Due to an Infection

    Time frame: Baseline to end of the study (up to 12 months)

  17. Changes in the Physical and Psychosocial Child Health Questionnaire-Parent Form Scores From Baseline to the End of the Study

    The Quality of Life (QoL) questionnaire Child Health Questionnaire-Parent Form (CHQ-PF50) was completed by a parent or guardian in study participants \< 14 years of age. The CHQ-PF50 consists of 50 items organized into 15 subscales.The 15 subscales could be combined into 2 summary scores, physical and psychosocial. The calculated summary scores were transformed to a range of 0-100, where a higher score indicates more positive functioning or better health status. A positive change score indicates improvement.

    Time frame: Baseline to end of the study (up to 12 months)

  18. Changes in the Physical and Mental Short Form-36 Health Survey Scores From Baseline to the End of the Study

    The Quality of Life (QoL) questionnaire Short Form-36 Health Survey (SF-36-HS) was completed by participants ≥ 14 years of age. The SF-36-HS consists of 36 items organized into 8 subscales. The 8 subscales could be combined into 2 summary scores, physical and mental. The calculated summary scores were transformed to a range of 0-100, where a higher score indicates better health. A positive change score indicates improvement.

    Time frame: Baseline to end of the study (up to 12 months)

07

Results

Posted Mar 16, 2017

Participant flow

Participant flow — Overall Study
MilestoneNewGam
Started51
Completed50
Not completed1
Withdrew: Investigator judgment1

Outcome measures

PrimaryNumber of Serious Bacterial Infections Per Person-year of Treatment

The number of serious bacterial infections per person-year of treatment was calculated by the following formula: Total number of serious bacterial infections / patient-years on NewGam treatment. Serious bacterial infections were defined as bacteraemia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Number · Serious infections per person-year of tr
Number of Serious Bacterial Infections Per Person-year of Treatment
Serious infections per person-year of trNewGam
Number of Serious Bacterial Infections Per Person-year of Treatment0.080
SecondaryIgG Trough Level Concentration

Total IgG trough concentrations were measured in serum samples taken before each infusion.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Mean · g/L
IgG Trough Level Concentration
g/LNewGam
Infusion 19.91 ± 2.845
Termination visit10.32 ± 3.429
SecondaryTrough Level Concentration of Antibodies Against Haemophilus Influenzae

Trough level concentrations of antibodies against Haemophilus influenzae were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Mean · µg/mL
Trough Level Concentration of Antibodies Against Haemophilus Influenzae
µg/mLNewGam
Infusion 11.96 ± 1.473
Termination visit2.51 ± 1.765
SecondaryTrough Level Concentration of Antibodies Against Measles

Trough level concentrations of antibodies against measles were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Mean · mIU/mL
Trough Level Concentration of Antibodies Against Measles
mIU/mLNewGam
Infusion 1854.08 ± 455.220
Termination visit1257.76 ± 706.276
SecondaryTrough Level Concentration of Antibodies Against Streptococcus Pneumoniae

Trough level concentrations of antibodies against Streptococcus pneumoniae (serotypes types 6B, 14, 9V, 18C, 19F, 4, and 23F) were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Mean · µg/mL
Trough Level Concentration of Antibodies Against Streptococcus Pneumoniae
µg/mLNewGam
Infusion 1 - serotype 41.03 ± 0.680
Termination visit - serotype 41.10 ± 0.673
Infusion 1 - serotype 6B1.97 ± 1.226
Termination visit - serotype 6B2.10 ± 1.134
Infusion 1 - serotype 9V1.86 ± 0.938
Termination visit - serotype 9V1.95 ± 0.942
Infusion 1 - serotype 147.21 ± 4.355
Termination visit - serotype 147.97 ± 5.057
Infusion 1 - serotype 18C2.28 ± 2.234
Termination visit - serotype 18C2.38 ± 2.077
Infusion 1 - serotype 19F6.56 ± 4.272
Termination visit - serotype 19F6.41 ± 3.843
Infusion 1 - serotype 23F1.87 ± 1.102
Termination visit - serotype 23F2.03 ± 0.918
SecondaryTrough Level Concentration of Antibodies Against Cytomegalovirus

Trough level concentrations of antibodies against cytomegalovirus were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Mean · U
Trough Level Concentration of Antibodies Against Cytomegalovirus
UNewGam
Infusion 130.75 ± 6.823
Termination visit30.16 ± 6.670
SecondaryTrough Level Concentration of Antibodies Against Tetanus

Trough level concentrations of antibodies against tetanus were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Mean · IU/mL
Trough Level Concentration of Antibodies Against Tetanus
IU/mLNewGam
Infusion 12.70 ± 1.467
Termination visit2.37 ± 1.389
SecondaryTrough Level Concentration of Antibodies Against Varicella-zoster Virus

Trough level concentrations of antibodies against varicella-zoster virus were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Mean · U/mL
Trough Level Concentration of Antibodies Against Varicella-zoster Virus
U/mLNewGam
Infusion 1125.13 ± 36.490
Termination visit119.02 ± 40.457
SecondaryTotal Number of Infections

The number of infections included serious bacterial infections (bacterial pneumonia, bacteraemia/sepsis, osteomyelitis/septic arthritis, visceral abscess, bacterial meningitis) and other infections. For other infections, the Medical Dictionary for Regulatory Activities (MedDRA) preferred term was used to determine the type of infection. They were grouped into the following categories as determined by a medical expert: Ear infections, eye infections, infections of the gastrointestinal tract, infections of the genitourinary tract, upper respiratory tract infections, lower respiratory tract infections, infections of the skin, and infections not elsewhere classified.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Number · Infections
Total Number of Infections
InfectionsNewGam
Total Number of Infections189
SecondaryNumber of Non-serious Infections

The MedDRA preferred term was used to determine the type of non-serious infection. They were grouped into the following categories as determined by a medical expert: Ear infections, eye infections, infections of the gastrointestinal tract, infections of the genitourinary tract, upper respiratory tract infections, lower respiratory tract infections, infections of the skin, and infections not elsewhere classified. The total number of infections and the number in each category are reported.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Number · Infections
Number of Non-serious Infections
InfectionsNewGam
All infections185
Ear infections13
Eye infections4
Infections of the gastrointestinal tract28
Infections of the genitourinary tract14
Upper respiratory tract infections90
Lower respiratory tract infections16
Infections of the skin5
Infections not elsewhere classified14
SecondaryTime to Resolution of Serious and Other Infections

Since infections were reported as adverse events, the time to resolution of an infection was the time from the start date of the infection adverse event to the end date of the infection adverse event.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Mean · Days
Time to Resolution of Serious and Other Infections
DaysNewGam
Serious infections14.3 ± 7.63
Other infections18.4 ± 34.82
SecondaryPercentage of Participants Treated With Antibiotics

The total percentage of participants treated with antibiotics, as well as, the percentage of participants treated with antibiotics therapeutically and prophylactically are reported.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Treated With Antibiotics
Percentage of participantsNewGam
Percentage of Participants Treated With Antibiotics82.4
SecondaryNumber of Antibiotic Treatment Episodes Per Person-year of Treatment

The number of antibiotic treatment episodes per person-year of treatment was calculated by the following formula: Total number of antibiotic treatment episodes / patient-years of NewGam treatment.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Number · Treatment episodes/person/year
Number of Antibiotic Treatment Episodes Per Person-year of Treatment
Treatment episodes/person/yearNewGam
Number of Antibiotic Treatment Episodes Per Person-year of Treatment3.045
SecondaryNumber of Antibiotic Treatment Days Per Person-year of Treatment

The number of antibiotic treatment days per person-year of treatment was calculated by the following formula: Total number of antibiotic treatment days / patient-years of NewGam treatment.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Number · Treatment days/person/year
Number of Antibiotic Treatment Days Per Person-year of Treatment
Treatment days/person/yearNewGam
Number of Antibiotic Treatment Days Per Person-year of Treatment87.301
SecondaryNumber of Participants Hospitalized Due to an Infection
Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Number · Participants
Number of Participants Hospitalized Due to an Infection
ParticipantsNewGam
Number of Participants Hospitalized Due to an Infection1
SecondaryPercentage of Participants With at Least 1 Episode of Fever
Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Episode of Fever
Percentage of participantsNewGam
Percentage of Participants With at Least 1 Episode of Fever21.6
SecondaryPercentage of Participants That Missed School or Work Due to an Infection
Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Number · Percentage of participants
Percentage of Participants That Missed School or Work Due to an Infection
Percentage of participantsNewGam
Percentage of Participants That Missed School or Work Due to an Infection49.0
SecondaryChanges in the Physical and Psychosocial Child Health Questionnaire-Parent Form Scores From Baseline to the End of the Study

The Quality of Life (QoL) questionnaire Child Health Questionnaire-Parent Form (CHQ-PF50) was completed by a parent or guardian in study participants \< 14 years of age. The CHQ-PF50 consists of 50 items organized into 15 subscales.The 15 subscales could be combined into 2 summary scores, physical and psychosocial. The calculated summary scores were transformed to a range of 0-100, where a higher score indicates more positive functioning or better health status. A positive change score indicates improvement.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Mean · Units on a scale
Changes in the Physical and Psychosocial Child Health Questionnaire-Parent Form Scores From Baseline to the End of the Study
Units on a scaleNewGam
Physical2.77 ± 9.89
Psychosocial0.26 ± 7.19
SecondaryChanges in the Physical and Mental Short Form-36 Health Survey Scores From Baseline to the End of the Study

The Quality of Life (QoL) questionnaire Short Form-36 Health Survey (SF-36-HS) was completed by participants ≥ 14 years of age. The SF-36-HS consists of 36 items organized into 8 subscales. The 8 subscales could be combined into 2 summary scores, physical and mental. The calculated summary scores were transformed to a range of 0-100, where a higher score indicates better health. A positive change score indicates improvement.

Time frame:
Baseline to end of the study (up to 12 months)
Reported as:
Mean · Units on a scale
Changes in the Physical and Mental Short Form-36 Health Survey Scores From Baseline to the End of the Study
Units on a scaleNewGam
Physical-2.23 ± 9.96
Mental2.59 ± 9.63

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NewGam—5/51 (9.8%)45/51 (88.2%)
Most frequent serious events
Most frequent serious events
EventNewGam
GoutMetabolism and nutrition disorders1/51
PneumoniaInfections and infestations1/51
BronchiectasisRespiratory, thoracic and mediastinal disorders1/51
BronchospasmRespiratory, thoracic and mediastinal disorders1/51
SeptoplastySurgical and medical procedures1/51
ThrombocytopeniaBlood and lymphatic system disorders1/51
Most frequent other events
Showing 10 of 35
Most frequent other events
EventNewGam
Upper respiratory tract infectionInfections and infestations15/51
HeadacheNervous system disorders14/51
NasopharyngitisInfections and infestations13/51
SinusitisInfections and infestations13/51
PyrexiaGeneral disorders11/51
FatigueGeneral disorders10/51
BronchitisInfections and infestations8/51
GastroenteritisInfections and infestations8/51
NauseaGastrointestinal disorders7/51
VomitingGastrointestinal disorders7/51

Baseline characteristics

Total set: All enrolled participants.

Age, Continuous
Age, Continuous(Years)NewGam
Mean26.8 ± 19.25
Sex: Female, Male
Sex: Female, Male(Participants)NewGam
Female18
Male33
08

Study locations

7 sites
  • Sudir Gupta, MD
    Irvine, California, United States
  • Isaac Melamed, MD
    Centennial, Colorado, United States
  • James Moy, MD
    Chicago, Illinois, United States
  • William Smits, MD
    Fort Wayne, Indiana, United States
  • Dr. Alan Knutsen
    St. Louis, Missouri 63104, United States
  • Ai Lan Kobayashi, MD
    Papillion, Nebraska, United States
  • Hans Ochs, MD
    Seattle, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2009
First posted
Nov 13, 2009
Start
Jan 2010
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Mar 16, 2017
Last update
Mar 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01012323
Lead sponsor
Octapharma
Collaborators
Premier Research Group plc
Responsible party
Sponsor
First posted
Nov 13, 2009
Start date
Jan 2010
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Mar 16, 2017
Last update
Mar 16, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion